1 active not recruiting, 1 withdrawn. 2 Phase 2, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 2 | Active not recruiting 1, Withdrawn 1 |
| Phase 1 | 1 | Withdrawn 1 |
Follow Recurrent Ovarian Seromucinous Carcinoma: new trials by email Literature Review of Recurrent Ovarian Seromucinous Carcinoma trials Research Report on Recurrent Ovarian Seromucinous Carcinoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Testing the Addition of ASTX660 (Tolinapant) to the Usual Chemotherapy Treatment (Paclitaxel With or Without Bevacizumab) in Patients With Recurrent Ovarian Cancer Bevacizumab, Biospecimen Collection, Computed Tomography - Platinum-Refractory Fallopian Tube Carcinoma, Platinum-Refractory Ovarian Carcinoma | Phase 1 / Phase 2 | Withdrawn | National Cancer Institute (NCI) | 2025-10-31 | 2025-06-03 | |
| Comparison of Standard of Care Treatment With a Triplet Combination of Targeted Immunotherapeutic Agents Biospecimen Collection, Cediranib Maleate, Computed Tomography - Fallopian Tube Mucinous Adenocarcinoma, Ovarian Seromucinous Carcinoma | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 120 | 2021-06-10 | 2026-10-22 |
Disulfides (2) · Immunoglobulin G (2) · Magnetic Resonance Spectroscopy (2) · Paclitaxel (2) · Specimen Handling (2) · Taxes (2) · ASTX-660 (1) · Bevacizumab (1) · Contrast Media (1) · Doxorubicin (1) · Topotecan (1) · cediranib (1) · durvalumab (1) · liposomal doxorubicin (1) · olaparib (1)
National Cancer Institute (NCI) (2)
Puerto Rico (1) · United States (1)
Jung-min Lee (1) · Kristen P Zeligs (1)
U10CA180868 (2)